ArticleCell death & disease2026

The CDK4/6 inhibitor dalpiciclib augments the antitumor efficacy of enzalutamide in preclinical models of castration-resistant prostate cancer through inhibition of MCM4-mediated DNA replication.

Yue Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.